In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...
Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...
13d
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Community driven content discussing all aspects of software development from DevOps to design patterns. The factorial of 5 is 120. The factorial of 10 is 3,628,800. Programmers can take one of two ...
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results